IL299789A - Combinations of MEK/RAF suppressor and anti-1-PD antibody for cancer therapy - Google Patents
Combinations of MEK/RAF suppressor and anti-1-PD antibody for cancer therapyInfo
- Publication number
- IL299789A IL299789A IL299789A IL29978923A IL299789A IL 299789 A IL299789 A IL 299789A IL 299789 A IL299789 A IL 299789A IL 29978923 A IL29978923 A IL 29978923A IL 299789 A IL299789 A IL 299789A
- Authority
- IL
- Israel
- Prior art keywords
- dosed
- antibody
- mek inhibitor
- subject
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051320P | 2020-07-13 | 2020-07-13 | |
| PCT/US2021/041439 WO2022015736A1 (en) | 2020-07-13 | 2021-07-13 | Combination therapy for treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299789A true IL299789A (en) | 2023-03-01 |
Family
ID=79554253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299789A IL299789A (en) | 2020-07-13 | 2021-07-13 | Combinations of MEK/RAF suppressor and anti-1-PD antibody for cancer therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230330088A1 (enExample) |
| EP (1) | EP4178573A4 (enExample) |
| JP (1) | JP2023534009A (enExample) |
| KR (1) | KR20230039684A (enExample) |
| CN (1) | CN116056699A (enExample) |
| AU (1) | AU2021307410A1 (enExample) |
| BR (1) | BR112023000675A2 (enExample) |
| CA (1) | CA3189383A1 (enExample) |
| IL (1) | IL299789A (enExample) |
| MX (1) | MX2023000589A (enExample) |
| WO (1) | WO2022015736A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115151533B (zh) | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
| WO2023138630A1 (zh) * | 2022-01-21 | 2023-07-27 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| EP4595963A4 (en) * | 2022-09-30 | 2026-01-21 | Inxmed Nanjing Co Ltd | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE |
| WO2024178274A2 (en) * | 2023-02-24 | 2024-08-29 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods of degrading raf(raf) protein in cells using mitogen-activated protein kinase kinase 1/2 (mek1/2) protein degraders |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014002353B1 (pt) * | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| ES2779975T3 (es) * | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| WO2015179075A1 (en) * | 2014-05-21 | 2015-11-26 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| BR112017000672A2 (pt) * | 2014-07-15 | 2017-11-14 | Genentech Inc | composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek |
| EA201890161A1 (ru) * | 2015-06-29 | 2018-06-29 | Верастэм, Инк. | Терапевтические композиции, комбинации и способы применения |
| CN109663130B (zh) * | 2017-10-13 | 2021-06-29 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 |
| WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
-
2021
- 2021-07-13 KR KR1020237004543A patent/KR20230039684A/ko active Pending
- 2021-07-13 BR BR112023000675A patent/BR112023000675A2/pt unknown
- 2021-07-13 IL IL299789A patent/IL299789A/en unknown
- 2021-07-13 MX MX2023000589A patent/MX2023000589A/es unknown
- 2021-07-13 AU AU2021307410A patent/AU2021307410A1/en active Pending
- 2021-07-13 WO PCT/US2021/041439 patent/WO2022015736A1/en not_active Ceased
- 2021-07-13 US US18/005,012 patent/US20230330088A1/en active Pending
- 2021-07-13 JP JP2023501802A patent/JP2023534009A/ja active Pending
- 2021-07-13 EP EP21841921.6A patent/EP4178573A4/en active Pending
- 2021-07-13 CA CA3189383A patent/CA3189383A1/en active Pending
- 2021-07-13 CN CN202180049487.0A patent/CN116056699A/zh active Pending
-
2026
- 2026-03-10 US US19/561,954 patent/US20260199339A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230330088A1 (en) | 2023-10-19 |
| EP4178573A4 (en) | 2024-08-07 |
| WO2022015736A9 (en) | 2022-05-05 |
| MX2023000589A (es) | 2023-02-13 |
| US20260199339A1 (en) | 2026-07-16 |
| CA3189383A1 (en) | 2022-01-20 |
| WO2022015736A1 (en) | 2022-01-20 |
| KR20230039684A (ko) | 2023-03-21 |
| JP2023534009A (ja) | 2023-08-07 |
| AU2021307410A1 (en) | 2023-02-09 |
| BR112023000675A2 (pt) | 2023-04-25 |
| CN116056699A (zh) | 2023-05-02 |
| EP4178573A1 (en) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yi et al. | Combination strategies with PD-1/PD-L1 blockade: current advances and future directions | |
| Dziadziuszko et al. | Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP) | |
| Jiang et al. | The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition | |
| Cai et al. | Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression | |
| TWI707692B (zh) | 用於治療非小細胞肺癌之抗ｂ７-ｈ１及抗ｃｔｌａ-４抗體 | |
| Searle et al. | Initial findings from a first-in-human phase 1a/b trial of NX-5948, a selective Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies | |
| CN107635583A (zh) | 用于治疗癌症的方法、组合物和试剂盒 | |
| CN107801379A (zh) | 抗癌剂 | |
| JP2023036999A (ja) | 免疫応答を調節するためのオキサビシクロヘプタン | |
| CN117653733B (zh) | 一种新免疫检查点piezo1通路在肿瘤t细胞治疗上的应用 | |
| Omar et al. | Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients’ response to cancer immunotherapy | |
| Vathiotis et al. | Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy | |
| Dedecker et al. | The role of immunotherapy in esophageal and gastric cancer | |
| Yu et al. | Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer | |
| Carter et al. | Immuno-oncology agents for cancer therapy | |
| Subbiah et al. | Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial | |
| Girard et al. | Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts | |
| Fallahi et al. | Novel treatment options for anaplastic thyroid cancer | |
| CA3164804A1 (en) | Once daily cancer treatment regimen with a prmt5 inhibitor | |
| CN110464845B (zh) | 一种用于乳腺癌免疫治疗的联合用药物组合及其应用 | |
| Nghiem et al. | Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up | |
| Fan et al. | Macrophage crosstalk and therapies: Between tumor cells and immune cells | |
| CN115463217B (zh) | 己酸羟孕酮在增强肿瘤治疗效果中的应用 | |
| Nishibata et al. | 986P Antitumor effect of zolbetuximab combined with chemotherapeutic agents or an anti-mPD-1 antibody in syngeneic immune-competent mice | |
| Hanna et al. | A phase I study of the next-generation farnesyltransferase inhibitor (FTI) KO-2806 as monotherapy in advanced solid tumors |